Acuta Capital Partners’s Bicycle Therapeutics BCYC Stock Holding History

Acuta Capital Partners’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-38,184	Closed	-$1.59M	–	40
2021 Q3	$1.59M	Buy	+38,184	New	+$1.34M	0.56%	37

Other funds holding BCYC

RCI

Ridgeback Capital Investments Miami Beach, Florida $560K AUM

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Acuta Capital Partners's BCYC Position: Q4 2021 in Review

Acuta Capital Partners sold out of Bicycle Therapeutics (BCYC) in Q4 2021, closing a stake of 38,184 shares — an estimated $1.59M sold.

Acuta Capital Partners first reported a position in BCYC in Q3 2021 and held it in 1 quarter. The position peaked at $1.59M in Q3 2021. 101 funds tracked by Wall St. Rank hold BCYC as of Q4 2021.

Acuta Capital Partners reported no remaining Bicycle Therapeutics position as of Q4 2021 after selling out during the quarter.
Acuta Capital Partners sold 38,184 Bicycle Therapeutics shares in Q4 2021, an estimated $1.59M.
Acuta Capital Partners first reported a position in Bicycle Therapeutics in Q3 2021 and held it in 1 quarter.
Acuta Capital Partners's Bicycle Therapeutics position peaked at $1.59M in Q3 2021.
101 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2021.

Based on Acuta Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.